Navigation Links
Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Date:9/18/2009

NATICK, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical program. PLATINUM is a global, randomized, pivotal controlled trial designed to support U.S. Food and Drug Administration (FDA) and Japanese Ministry of Health, Labor and Welfare (MHLW) approval of the platinum chromium PROMUS((R)) Element(TM) Everolimus-Eluting Coronary Stent System. The trial enrolled 1,532 patients with up to two de novo lesions at more than 140 sites worldwide, and completed enrollment two months ahead of schedule.

The PLATINUM workhorse trial evaluates the new PROMUS Element Everolimus-Eluting Coronary Stent in comparison with the current PROMUS Stent, which uses the same drug dose and polymer on an earlier cobalt chromium alloy stent design. Two parallel sub-trials will evaluate the PROMUS Element Stent in small vessels and long lesions. In addition to the PROMUS Element Everolimus-Eluting Stent, the Company is developing additional variations of a bare-metal and paclitaxel-eluting stent on the Element platform. The pivotal PERSEUS clinical trial compares the TAXUS((R)) Element(TM) Stent to the TAXUS Express2(TM) Stent. The PERSEUS trial completed enrollment in October 2008, and the primary endpoint will be reported at the ACC conference in 2010.

"The brisk enrollment in the PLATINUM trial reflects the strong interest in this new platinum chromium stent platform," said Gregg W. Stone, M.D., Professor of Medicine and the Director of Research and Education at the Center for Interventional Vascular Therapy at the Columbia University Medical Center/New York-Presbyterian Hospital and Principal Investigator of the trial.

The Element Stent platform features a proprietary platinum chromium alloy, designed specifically for coronary stents. This alloy, coupled with a new stent architecture, is designed to allow thinner struts, increased flexibility and a lower profile, while improving radial strength, recoil and visibility. In addition, all three Element Stents incorporate the new Apex(TM) Dilatation Catheter technology, designed to enhance deliverability.

"We are pleased to bring the next-generation Element drug-eluting stent platform another step closer to commercialization," said Hank Kucheman, Senior Vice President and Group President, Cardiovascular for Boston Scientific. "We are confident that the next-generation Element platform - to be offered in everolimus, paclitaxel and bare-metal versions - will further extend our global drug-eluting stent leadership."

The PROMUS Element, TAXUS Element and bare-metal Element Stents are investigational devices and are limited by applicable law to investigational use only and are not available for sale.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

    CONTACT:  Paul Donovan
              508-650-8541 (office)
              508-667-5165 (mobile)
              Media Relations
              Boston Scientific Corporation

              Larry Neumann
              508-650-8696 (office)
              Investor Relations
              Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientifics Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network
2. Boston Scientific Statement on the Passing of Senator Edward Kennedy
3. Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
4. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
5. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
6. Boston Scientific to Participate in Wachovia Conference
7. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
8. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
9. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
10. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
11. Boston Scientific Welcomes Launch of Syntax Score Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
Breaking Biology News(10 mins):